"The submission of PORTICO-2 to the FDA marks a major step forward for Oryzon and for the field of neuropsychiatry of personality disorders," said Carlos Buesa, Chief Executive Officer of Oryzon.

Amycretin helped patients lose over 24% of their weight, compared with an average of about 17% for Wegovy.

Researchers at the Center for Medicinal Cannabis Research at University of California San Diego School of Medicine have found ...

Summary:A new clinical trial found that cannabidiol (CBD) is safe and potentially helpful in reducing problematic behaviors ...

SEOUL, June 23 — BTS member Suga has donated five billion won (US$3.62 million) to establish a treatment centre dedicated to ...